Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Poly-ICLC and Radiation Therapy in Newly Diagnosed Glioblastoma
NCT00052715Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Oct 2002
- Primary completion
- Feb 2006
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of poly iclc in glioblastoma multiforme (GBM), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Overall Survival at 2 years. Started Oct 2002; status: terminated.
02
Drugs
poly iclc
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00052715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00052715.